Literature DB >> 10646909

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.

H Lage1, H Helmbach, M Dietel, D Schadendorf.   

Abstract

The role of DNA topoisomerases (Topo) IIalpha and IIbeta was investigated in various drug-resistant melanoma cells. Melanoma cells resistant to etoposide, exhibited an up to tenfold reduced Topo II activity corresponding to an increasing degree of drug resistance indicating that modulation of Topo II activity contribute to the drug-resistant phenotype. The reduction of Topo II activity was reflected by decreased nuclear amounts of both Topo II isoforms.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10646909      PMCID： PMC2363299          DOI： 10.1054/bjoc.1999.0947

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  17 in total

1.  Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.

Authors:  H Takano; K Kohno; M Ono; Y Uchida; M Kuwano
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

2.  Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes.

Authors:  P R Walker; C Smith; T Youdale; J Leblanc; J F Whitfield; M Sikorska
Journal:  Cancer Res       Date:  1991-02-15       Impact factor: 12.701

3.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

4.  Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.

Authors:  Y S Son; J M Suh; S H Ahn; J C Kim; J Y Yi; K C Hur; W S Hong; M T Muller; I K Chung
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

Review 5.  Mechanism of action of topoisomerase II-targeted antineoplastic drugs.

Authors:  N Osheroff; A H Corbett; M J Robinson
Journal:  Adv Pharmacol       Date:  1994

6.  Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.

Authors:  U Kellner; L Hutchinson; A Seidel; H Lage; M K Danks; M Dietel; S H Kaufmann
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

7.  Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.

Authors:  M A Kern; H Helmbach; M Artuc; D Karmann; K Jurgovsky; D Schadendorf
Journal:  Anticancer Res       Date:  1997 Nov-Dec       Impact factor: 2.480

8.  Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.

Authors:  J A Campain; R Padmanabhan; J Hwang; M M Gottesman; I Pastan
Journal:  J Cell Physiol       Date:  1993-05       Impact factor: 6.384

9.  Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.

Authors:  M K Danks; M R Warmoth; E Friche; B Granzen; B Y Bugg; W G Harker; L A Zwelling; B W Futscher; D P Suttle; W T Beck
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

10.  A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.

Authors:  J A Campain; M M Gottesman; I Pastan
Journal:  Biochemistry       Date:  1994-09-20       Impact factor: 3.162
View more
  10 in total

1.  RAD001 can reverse drug resistance of SGC7901/DDP cells.

Authors:  Liu Ying; Zhu Zu-An; Liu Qing-Hua; Kong Qing-Yan; Liu Lei; Cui Tao; Wu Yong-Ping
Journal:  Tumour Biol       Date:  2014-06-12

2.  The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.

Authors:  Elisabeth J Walsby; Steven J Coles; Steven Knapper; Alan K Burnett
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

3.  Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.

Authors:  Luke Pett; Konstantinos Kiakos; Vijay Satam; Pravin Patil; Sarah Laughlin-Toth; Matthew Gregory; Michael Bowerman; Kevin Olson; Mia Savagian; Megan Lee; Moses Lee; W David Wilson; Daniel Hochhauser; John A Hartley
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2016-10-24       Impact factor: 4.490

4.  Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.

Authors:  Nathalie Vilain; Monika Tsai-Pflugfelder; Audrey Benoit; Susan M Gasser; Didier Leroy
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

5.  Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.

Authors:  Suzan McNamara; Hongling Wang; Nessrine Hanna; Wilson H Miller
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

6.  Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR.

Authors:  Wing Pui Tsang; Timothy W L Wong; Albert H H Cheung; Chloe N N Co; Tim Tak Kwok
Journal:  RNA       Date:  2007-04-06       Impact factor: 4.942

7.  Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.

Authors:  Bálint Tegze; Zoltán Szállási; Irén Haltrich; Zsófia Pénzváltó; Zsuzsa Tóth; István Likó; Balázs Gyorffy
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

8.  GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.

Authors:  Fang Li; Qinyun Xia; Lian Ren; Yuhong Nie; He Ren; Xiaoyu Guo; Jinqiang Yu; Yiqiao Xing; Zhen Chen
Journal:  Oxid Med Cell Longev       Date:  2022-03-29       Impact factor: 7.310

Review 9.  Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.

Authors:  Bhuvanesh Sukhlal Kalal; Dinesh Upadhya; Vinitha Ramanath Pai
Journal:  Oncol Rev       Date:  2017-03-24

10.  Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.

Authors:  Amram O Williams; Richard J Isaacs; Kathryn M Stowell
Journal:  BMC Mol Biol       Date:  2007-05-20       Impact factor: 2.946
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.